<SEC-DOCUMENT>0001193125-18-205811.txt : 20180627
<SEC-HEADER>0001193125-18-205811.hdr.sgml : 20180627
<ACCEPTANCE-DATETIME>20180627164107
ACCESSION NUMBER:		0001193125-18-205811
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180627
DATE AS OF CHANGE:		20180627

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTREXON CORP
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-220326
		FILM NUMBER:		18922205

	BUSINESS ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060
		BUSINESS PHONE:		301-556-9809

	MAIL ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTREXON CORP
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060
		BUSINESS PHONE:		301-556-9809

	MAIL ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d640685dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g640685g0627224237395.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-220326</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus dated June&nbsp;27, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Relating to Preliminary Prospectus Supplement dated June&nbsp;27, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(To Prospectus dated September&nbsp;1, 2017) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GERMANTOWN, Md., June&nbsp;27, 2018 /PRNewswire/ &#151;&nbsp;Intrexon Corporation (NYSE: XON) (the &#147;Company&#148;) today announced that it intends to
offer and sell, subject to market and other conditions, $200.0&nbsp;million aggregate principal amount of its Convertible Senior Notes due 2023 (the &#147;Notes&#148;) in an underwritten offering registered with the Securities and Exchange
Commission (the &#147;SEC&#148;). The Company expects to grant the underwriters of the Notes a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional $30.0&nbsp;million aggregate principal amount of Notes, solely to
cover over-allotments, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes will be senior unsecured obligations of the Company, and interest will be payable semi-annually in arrears. The
Notes will be convertible into cash, shares of the Company&#146;s common stock (&#147;Common Stock&#148;) or a combination thereof, at the Company&#146;s election. The interest rate, conversion rate and other terms of the Notes will be determined
upon pricing of the offering of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the offering of the Notes, the Company intends to offer shares of its common stock (the
&#147;Common Stock&#148;) at an aggregate public offering price of $100,000,000 in a separate <FONT STYLE="white-space:nowrap">SEC-registered</FONT> offering. Such shares (the &#147;Borrowed Shares&#148;) will be loaned by the Company to J.P. Morgan
Securities LLC (in such capacity, the &#147;Share Borrower&#148;), the underwriter of the offering of Borrowed Shares, pursuant to a share lending agreement. The Company has been informed by the Share Borrower that it or one of its affiliates
intends to sell the Borrowed Shares and use the resulting short position to facilitate transactions by which investors in the Notes may hedge their investments through short sales or privately negotiated derivatives transactions. The Share Borrower
will be required to return the Borrowed Shares (or identical shares of Common Stock) to the Company pursuant to the terms of the share lending agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds received from the Notes offering for general corporate purposes and for strategic acquisitions. The Share Borrower
or its affiliates will receive all of the proceeds of the offering of the Borrowed Shares, and the Company will not receive any proceeds of that offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Randal J. Kirk, the Chairman, Chief Executive Officer and principal shareholder of the Company, has indicated that he or an entity with which he is affiliated
may have interest in purchasing at the public offering price up to all of the Borrowed Shares. The ultimate allocation of the Borrowed Shares will be determined by the underwriter of the Borrowed Shares, and Mr.&nbsp;Kirk or such entity may or may
not purchase some or all of the Borrowed Shares. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of the Notes is contingent upon the closing of the offering of the Borrowed Shares, and the offering
of the Borrowed Shares is contingent upon the closing of the offering of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC will act as sole bookrunner for the
offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Notes offering and the Borrowed Shares offering may be made only by means of a prospectus supplement and an accompanying
prospectus. When available, copies of the applicable preliminary prospectus supplement and the accompanying prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-803-9204.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes, the Borrowed Shares or any other securities, nor
will there be any sale of the Notes, the Borrowed Shares or any other securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements
regarding the anticipated final terms, timing and completion of the proposed offerings. All statements, other than statements of historical facts regarding our strategies, prospects, financial condition, costs, plans and objectives are
forward-looking statements. These forward-looking statements reflect our beliefs and expectations as to future events and trends affecting our business, our consolidated financial condition and results of operations. These forward-looking statements
are based upon our current expectations concerning future events and discuss, among other things, anticipated future financial performance and future business plans. Forward-looking statements are necessarily subject to risks and uncertainties, many
of which are outside our control, that could cause actual results to differ materially from these statements. Forward-looking statements can be identified by such words as &#147;anticipates,&#148; &#147;believes,&#148; &#147;plan,&#148;
&#147;assumes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;potential,&#148; &#147;seek,&#148; &#147;predict,&#148; &#147;may,&#148; &#147;will&#148; and similar expressions.
These forward-looking statements include, among other things, statements about, our strategy and overall approach to our business model, our ability to successfully enter new markets or develop additional products, whether with our collaborators or
independently, our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future, competition from existing technologies and products or new technologies and products
that may emerge, actual or anticipated variations in our operating results, our current and future joint ventures, or JVs, exclusive channel collaborations, or ECCs, license agreements and other collaborations, developments concerning our
collaborators and licensees, actual or anticipated fluctuations in our competitors&#146; or our collaborators&#146; and licensees&#146; operating results or changes in their respective growth rates, our cash position, market conditions in our
industry, our ability to protect our intellectual property and other proprietary rights and technologies, our ability to adapt to changes in laws or </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
regulations and policies, the ability of our collaborators and licensees to adapt to changes in laws or regulations and policies and to secure any necessary regulatory approvals to commercialize
any products developed under the ECCs, license agreements and JVs, the ability of our collaborators and licensees to protect our intellectual property and other proprietary rights and technologies, the ability of our collaborators and licensees to
develop and successfully commercialize products enabled by our technologies, the rate and degree of market acceptance of any products developed by our subsidiaries, a collaborator under an ECC, or through a JV or license under a license agreement,
our ability to retain and recruit key personnel, the result of litigation proceedings that we face currently or may face in the future, our expectations related to the use of proceeds from our public offerings and other financing efforts, our
estimates regarding expenses, future revenue, capital requirements and needs for additional financing and the impact of the Tax Cuts and Jobs Act of 2017, or the Tax Act, on our current and future operating results. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on
our forward-looking statements. Item 1A, &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and Item 1A, &#147;Risk Factors&#148; in our Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three months ended March&nbsp;31, 2018, include factors that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. Forward-looking statements may also concern our expectations relating to our subsidiaries and other
affiliates. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All information in this press release is as of the date of the release, and we do not assume any obligation to update any
forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existence of the share
lending agreement in connection with the offering of the Borrowed Shares, the short sales of the Common Stock effected in connection with the sale of the Notes and the related derivatives transactions, or any unwind of such short sales or
derivatives transactions, could cause the market price of the Common Stock to be lower over the term of the share lending agreement than it would have been had the Company not entered into that agreement, due to the effect of the increase in the
number of outstanding shares of Common Stock or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes and the Borrowed Shares are being offered by the Company pursuant to an
automatically effective shelf registration statement that was previously filed with the SEC. Before you invest, you should read the preliminary prospectus supplements relating to and describing the terms of the offerings in that registration
statement and other documents the Company has filed with the SEC for more complete information about the Company and the offerings. The preliminary prospectus supplements will be filed with the SEC and will be available for free by visiting EDGAR on
the SEC&#146;s website at www.sec.gov. When available, copies of the preliminary prospectus supplements and the accompanying prospectus relating to the Notes and the Borrowed Shares, respectively, may also be obtained by contacting J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-803-9204.</FONT></FONT></FONT> The final terms of the each of the offerings will be disclosed in final prospectus supplements to be filed with
the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intrexon Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon
Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA&#153; to create biologically-based products that improve the quality of life and the health of the planet. Intrexon&#146;s integrated technology suite provides its
partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For More Information: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Contact:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Corporate Contact:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thomas Shrader, PhD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Marie Rossi, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vice President, Communications&nbsp;&amp; Strategy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, Technical Communications</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>investors@dna.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel: +1 (301) <FONT STYLE="white-space:nowrap">556-9850</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>publicrelations@dna.com</U></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g640685g0627224237395.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g640685g0627224237395.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P -L# 2(  A$! Q$!_\0
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MP-;MHMV'O=:AS:R1GF.(CYI/8X.![GVKY^^(/@VX\#^*[C3)-SVK?O;28_\
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M5;:4&?RCL!(X^;&*\_O="UAK^X8:3?D&5B#]F?U/M0!]-_ 7_DEEI_U\3?\
MH59?[16ERW?@>SOXE++97@,F.RN"N?SVC\:V?@;;3VGPQM8KF"6&07$Q*2(5
M/WO0UWFIZ;::QI=SIU]")K6YC,<J'N#_ %]Z /A33S9C4;8Z@LK6?FKYZPL
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MPCL-+O;J0G&(8&?^0H SP"2 !DGH!7J'Q<TJ71-)\$Z;.-LT&D 2+Z.6RP_
MDUV7PM^"-U9ZC;Z]XJC2,P,)+>PR&.X<AI,<<==OKU]#5_:*TZ^O?$.BM:65
MS<*MHX8Q1,P'S^PH Y+X#?\ )5++_KWF_P#0#7UI7RO\#M*U&T^)]G+<Z?=P
MQB"8%Y(64#Y#W(KZHH ^'/&?_(\^(/\ L(W'_HQJPZZOQAHFK2^-=>DCTN]=
>&U"<JRV[D$>8W(XK%_L#6?\ H$7_ /X#/_A0!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
